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Department of Clinical Physiology and Nuclear Medicine, 239, Hvidovre Hospital, Faculty of Health Sciences, University of Copenhagen, DenmarkIncreased cardiac output was ﬁrst described in patients with Introduction
cirrhosis more than ﬁfty years ago. Later, various observations
have indicated the presence of a latent cardiac dysfunction,
which includes a combination of reduced cardiac contractility
with systolic and diastolic dysfunction and electrophysiological
abnormalities. This syndrome is termed cirrhotic cardiomyopa-
thy. Results of experimental studies indicate the involvement
of several mechanisms in the pathophysiology, such as
reduced b-adrenergic receptor signal transduction, altered
transmembrane currents and electromechanical coupling, nitric
oxide overproduction, and cannabinoid receptor activation.
Systolic incompetence in patients can be revealed by pharma-
cological or physical strain and during stressful procedures,
such as transjugular intrahepatic portosystemic shunt insertion
and liver transplantation. Systolic dysfunction has recently
been implicated in development of renal failure in advanced
disease. Diastolic dysfunction reﬂects delayed left ventricular
ﬁlling and is partly attributed to ventricular hypertrophy, sub-
endocardial oedema, and altered collagen structure. The QT
interval is prolonged in about half of the cirrhotic patients
and it may be normalised by b-blockers. No speciﬁc therapy
for cirrhotic cardiomyopathy can be recommended, but treat-
ment should be supportive and directed against the cardiac
dysfunction. Future research should better describe the preva-
lence, impact on morbidity and survival, and look for potential
treatments.
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tumour necrosis factor-a.Deterioration of liver function was ﬁrst associated with the func-
tion of the cardio-vascular system via a hyperdynamic circulation
that was described in these patients more than ﬁfty years ago [1].
Later it became clear that cirrhotic patients exhibit a circulatory
and cardiac dysfunction predominantly governed by peripheral
vasodilatation [2,3]. There is now substantial evidence that
impaired liver function and portal hypertension with splanchnic
vasodilatation lead to the development of a hyperdynamic syn-
drome [3,4]. Redistribution of the circulating blood volume
results in a reduced central blood volume with central or ‘‘effec-
tive” hypovolaemia [3]. Low effective blood volume (central and
arterial volume) in combination with arterial hypotension, lead
to volume- and baroreceptor activation of potent vasoconstrict-
ing systems, such as for example the sympathetic nervous system
[5]. This further aggravates the hyperdynamic circulation and
cardiac strain. Results of experimental and clinical studies have
shown impaired myocardial contractility as well as electrophys-
iological abnormalities in cirrhosis, which have led to a clinical
entity called ‘‘cirrhotic cardiomyopathy” [6,7]. This term denotes
a chronic cardiac dysfunction, characterised by blunted contrac-
tile responsiveness to stress and altered diastolic relaxation with
electrophysiological abnormalities, such as prolongation of the
QT interval, all occurring in the absence of any other cardiac dis-
ease [8,9]. This cardiac dysfunction may affect the prognosis of
the patients and aggravate the course during invasive procedures
such as surgery, insertion of a transjugular intrahepatic portosys-
temic shunts (TIPS), and liver transplantation [10,11]. On the
other hand, liver transplantation has also been shown to amelio-
rate the cardiac and circulatory disturbances [12].
This review seeks to describe the elements of the cirrhotic car-
diomyopathy, the pathophysiological background, the impact on
the course of the disease, aspects of treatment, and future
strategies.Experimental evidence of cirrhotic cardiomyopathy
Physiological and biochemical abnormalities in cirrhotic models
may differentially affect cardiac function with respect to the con-
trol of heart rate, contractility, conduction, and repolarisation.
Arterial vasodilatation, increased cardiac output, and increased
heart rate characterise the circulation in cirrhotic animal models
[13]. Effective hypovolaemia activates the sympathetic nervous
system (SNS) and the renin-angiotensin-aldosterone system
(RAAS) both ofwhich signiﬁcantly contribute to the hyperdynamic10 vol. 53 j 179–190
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circulatory state in cirrhosis [14–16]. In addition to being hyperdy-
namic, the circulation in cirrhosis is also hyporeactive with
reduced vascular reactivity to adrenaline and angiotensin-II most
likely because of increased release of nitric oxide (NO) [17–21].
An autonomic dysfunction that involves the sympathetic as well
as the parasympathetic branch also seems to play a role [22–24].
This has been veriﬁed in cirrhotic patients by applying standard
cardiovascular reﬂex tests, for example to measure heart rate var-
iability, response to head-up tilt, and baroreﬂex-sensitivity
[5,25,26].Most of the results of these tests are impaired in cirrhosis
and the autonomic dysfunction may therefore interact with the
cardiac performance.
Results of many experimental studies in cirrhotic models have
shown reduced cardiac performance with impaired cardiac con-
tractility and limited preload reserve, but of different pathophys-
iological mechanisms (Fig. 1).
In the face of an activated SNS, Gerbes et al. found a decreased
density of b-adrenoceptors in leucocytes from cirrhotic patients
as evidence of the down-regulation of b-adrenoceptors [27]. LeeAC 
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180 Journal of Hepatology 201et al. expanded these results in a cirrhotic rat model by showing
evidence of desensitisation of myocardial b-adrenergic receptors,
indicating that down-regulation of b-adrenergic receptors could
be responsible for the myocardial hyporesponsiveness to cate-
cholamines [28]. Another important mechanism to be considered
is the nitration of proteins, which may be harmful to their func-
tion. Thus, Mani et al. recently showed that nitration of cardiac
proteins led to an abnormal cardiac chronotropic function and
thereby impairment of control of heart rate in cirrhotic cardiomy-
opathy [29].
The contractility of the heart muscle cell can be disturbed in
different ways, but the molecular mechanisms of the decreased
contractility are not completely understood. There is however,
experimental evidence of decreased responsiveness of cardio-
myocytes to b-adrenergic agonists. The b-adrenergic receptors
are located in the cell membrane, and altered physical properties
with increased ﬂuidity of the cardiomyocyte plasma membrane
may be associated with the decreased b-adrenoceptor function
[30]. Thus, changes in the cardiomyocyte plasma membraneNO  
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cholesterol/phospholipid ratio) also contribute to reduced calcium release and
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may affect b-adrenergic receptors, signalling function, and car-
diac contractility [31,32]. Recently, Ceolotto and co-workers
demonstrated that the reduced b-adrenergic-dependent inotro-
pic effect could partly be attributed to an over-expression of
proteins such as inhibitory G-protein (Gai) and regulators of G-
protein signalling (RGS2) that inhibit the adenylate cyclase and
those that accelerate degradation of cAMP such as phosphodies-
terase (PDE2) [33], Fig. 1. Thus, abnormal gene expression of the
b-adrenergic system may be involved in the abnormal signal
transduction and altered myocardial contractility in cirrhotic car-
diomyopathy [33]. In addition, there is experimental evidence for
the involvement of the parasympathetic nervous system,
although parasympathetic dysfunction appears somewhat com-
plex. The myocardial contractile responsiveness to muscarinic
stimulation is attenuated in cirrhotic rats but the changes are
likely compensatory, suggesting post-receptor factors [34]. Thus,
it is less likely that the muscarinic over-activity is directly
involved in the cirrhotic cardiomyopathy.
The endogenous and exogenous cannabinoids (CB) belong to a
system of cellular signalling pathways acting via CB1 receptors,
whose activation induces arterial hypotension. The endocannab-
inoids inﬂuence the vascular tone by a vasodilatory effect that
activates G-proteins; an effect that is ampliﬁed by the ability of
endocannabinoids to induce apoptosis of hepatic stellate cells,
thus favouring the development of portal hypertension and
hyperdynamic circulation [35,36]. There is evidence of increased
local ventricular endocannabinoid production in cirrhosis and
that activation of CB1 receptors by endogenous anandamide con-
tributes to the reduced cardiac contractility in cirrhosis [37].
Antagonist blockade of the CB1 receptors may reverse the
impaired cardiac contractility, and studies in a model of CCl4-
induced cirrhotic rats by the use of CB1 receptor antagonists have
shown an improvement in the contractile function in cirrhotic
cardiomyopathy [37,38]. Future clinical studies should focus on
the potential therapeutic beneﬁts of CB1 antagonism.
As mentioned above, there is experimental evidence that NO
is involved in the vascular hyporesponsiveness to vasoconstric-
tors [18,19]. Furthermore, NO has been shown to modify cardiac
performancewithsigniﬁcant impairmentof thecardiaccontractility
in bile duct-ligated cirrhotic rats [39,40]. Results of additional
experimental studies have indicated that the cytokine–NO path-
way occurs in cirrhotic rat hearts with enhanced expression of
the NO synthase [20,41] and that inhibition of the NO synthesis
by the NO inhibitor L-NAME reverses the impaired cardiac con-
tractility [39,41]. In a model of chronic bile duct ligation-induced
cirrhosis, portal hypertension induced a marked left ventricular
hypertrophy with increased myocardial NO synthesis, but in this
model without any functional impairment [42]. Defects in con-
tractile and connective proteins may play a role in the impaired
systolic and diastolic function. In bile duct-ligated rats, over-
expression of the b-myosin heavy chain in the cirrhotic heart
seems to play a role in the impaired systolic function [43], and
an altered ratio of the stiffer collagen I and the more compliant
collagen III along with titins could play a role in the decreased
compliance in the cirrhotic heart and the diastolic dysfunction
[44]. Activation of the haemoxygenase-carbon monoxide path-
way may also occur in cirrhotic rat hearts with expression of
haemoxygenase-1 [45]. Inhibition of the effects of carbon monox-
ide improves cardiac contractility and may play an important role
in the pathogenesis of cirrhotic cardiomyopathy [40,45]. Nuclear
factor-jB regulates different cytokines such as tumour necrosisJournal of Hepatology 201factor-a (TNF-a) and seems activated in cirrhotic rat hearts
[46]. Activation of nuclear factor-jB, a transcription factor that
regulates inﬂammatory processes, suppresses cardiac contractil-
ity and its inhibition improves systolic and diastolic contractility,
which emphasises a role of cytokine expression in cirrhotic car-
diomyopathy [46].
Abnormalities in the properties of the plasma membrane
affect repolarisation and conduction. The plasma membrane ﬂu-
idity of the cardiomyocyte is changed in models of cirrhotic car-
diomyopathy and the membrane lipid content is abnormal with
an increased cholesterol and thereby an increased cholesterol/
phospholipid ratio [47]. As this determines the characteristics
of the membrane and its membrane-bound proteins, the function
of ion channels, for instance, may be signiﬁcantly changed. Thus,
Ward et al. found a decreased density of potassium currents in
ventricular myocytes, which may contribute to prolong the QT
interval [48]. In the same model of bile duct-ligated rats, the
same group found a reduced expression and density of L-type
Ca++ channels and of inward cellular calcium current; therefore
modiﬁcations of the cellular calcium regulatory system with
reduced calcium inﬂux contributes to the reduced cardiac con-
tractility (Fig. 1) [49]. In a model of portal vein-ligated rats,
Zavecz et al. similarly reported a reduction of the density of L-
type Ca++ channels and the sarcoplasmic reticulum Ca++ pool as
a cause of changed excitation–contraction coupling [50]. Changes
in the calcium channels also contribute to the prolonged QT
interval, which has an arrythmogenic effect. However, in differ-
ent rat models, NO reduces the susceptibility to adrenaline-
induced arrhythmia, which could counteract the pro-arrythmo-
genic effect of a QT prolongation [51].
In conclusion, cirrhotic models supply a considerable amount
of experimental evidence for the reduced cardiac contractility.
The pathophysiology behind the reduced contractility is complex,
but different ﬁndings have contributed towards a better under-
standing of the pathophysiological background of cirrhotic car-
diomyopathy, such as the down-regulation of b-receptors along
with an impaired b-adrenergic signalling, changed plasma mem-
brane ﬂuidity with altered potassium, calcium channels and elec-
trophysiological abnormalities, activation of the cannabinoid, NO
and cytokine systems, as well as abnormal myoﬁlaments.Cirrhotic cardiomyopathy in patients
Systolic dysfunction
The systolic function closely relates to the size of the stroke vol-
ume, heart rate, and cardiac output. In cirrhosis, the circulatory
dysfunction has been expressed as a hyperdynamic unloaded fail-
ure of the heart [52]. Despite the characteristic high cardiac out-
put, a systolic dysfunction is included in the working deﬁnition of
the cirrhotic cardiomyopathy (Table 1) [9]. However, at rest, the
cardiac pressures are normal in the majority of cirrhotic patients
[52,53]. Physical exercise, however, increases left ventricular
pressures in some patients [54,55] and induces a relatively smal-
ler increase in the left-ventricular ejection fraction and heart rate,
Table 2 [56]. Although sympathetic nervous tone is increased
during exercise, cardiac performance is reduced because of
reduced cardiovascular reactivity [57].
Administration of vasoconstrictors, such as angiotensin II
and terlipressin, increases the systemic vascular resistance0 vol. 53 j 179–190 181
Table 1. Proposal for diagnostic and supportive criteria for cirrhotic cardio-
myopathy agreed upon at a working party held at the 2005 World Congress of
Gastroenterology in Montreal.
A working deﬁnition of cirrhotic cardiomyopathy
A cardiac dysfunction in patients with cirrhosis characterised by
impaired contractile responsiveness to stress and/or altered diastolic
relaxation with electrophysiological abnormalities in the absence of
other known cardiac disease
Diagnostic criteria
Systolic dysfunction
 Blunted increase in cardiac output with exercise, volume challenge or
pharmacological stimuli
 Resting EF <55%
Diastolic dysfunction
 E/A ratio <1.0 (age-corrected)
 Prolonged deceleration time (>200 msec)
 Prolonged isovolumetric relaxation time (>80 msec)
Supportive criteria
 Electrophysiological abnormalities
 Abnormal chronotropic response
 Electromechanical uncoupling/dyssynchrony
 Prolonged QTc interval
 Enlarged left atrium
 Increased myocardial mass
 Increased BNP and pro-BNP
 Increased troponin I
BNP, brain natriuretic peptide; E/A, early diastolic/atrial ﬁlling ratio; EF, left-
ventricular ejection fraction.
Reviewand thereby the left ventricular afterload [3,58–60]. Pharmaco-
logical or physical stress may unmask a latent left ventricular
dysfunction in patients with cirrhosis, as evidenced by an
increase in left ventricular end-diastolic volume and a decreaseTable 2. Potential cardiovascular changes in cirrhotic cardiomyopathy at rest
and during pharmacological or physical stress.
At rest
Heart
Heart rate "
Cardiac output "
Left atrial volume "
Left ventricular volume ? (")
Right atrial volume? " ;
Right atrial pressure ? "
Right ventricular end-diastolic pressure ?
Pulmonary artery pressure ? "
Pulmonary capillary wedge pressure ?
Left atrial pressure ?
Left ventricular end-diastolic pressure ?
Systemic circulation
Plasma volume "
Total blood volume "
Non-central blood volume "
Central and arterial blood volume ? ;
Cardiac output (?) " (;)
Arterial blood pressure ? ;
Heart rate "
Systemic vascular resistance ;
During stress
Peak heart rate ;
Peak work rate ;
Peak exercise blood pressure ;
Blood pressure  heart rate product ;
Left atrial pressure "
Left ventricular volume "
Peak cardiac output ;
Peak left-ventricular ejection fraction ;
",?, ; denote increased, unchanged, and decreased values compared to controls.
Arrows in parentheses describe less typical changes.
182 Journal of Hepatology 201in left-ventricular ejection fraction (Table 2) [61]. Infusion of
angiotensin II in cirrhotic patients elicits an abnormal response
in terms of a 30% increase in the left ventricular afterload and
results in a doubling of the pulmonary capillary wedge pressure
without changes in the cardiac output [58]. Dobutamine infu-
sion increases the cardiac work by elevating the cardiac output
and heart rate but with smaller changes in cardiac pressures
[59]. In cirrhotic patients, a dobutamine stress test could be
used to reveal a cardiac dysfunction [62]. In the preoperative
assessment of patients with end-stage liver disease, a dobuta-
mine stress echocardiography revealed ventricular dysfunction
in fewer than 10% of the patients, but the predictive values of
this test are not known [60]. In accordance with these ﬁndings,
recent data from our group indicate that cirrhotic cardiomyop-
athy may be less frequently revealed by dobutamine, at least in
patients with mild disease [63]. Therefore, at present the dobu-
tamine test cannot be recommended for the diagnosis of cir-
rhotic cardiomyopathy, but should be reserved for severe
ischaemic heart disease before transplantation.
Analogously to the normal resting cardiac pressures in cirrho-
sis, changes in the size of the cardiac volumes are only modest. As
assessed by magnetic resonance imaging, there seems to be a
trend towards slightly increased left ventricular end-diastolic
and left atrial volumes, probably in relation to the presence of
diastolic dysfunction [64–66]. Increased atrial natriuretic peptide
(ANP) in some patients with cirrhosis may reﬂect distension or
distortion of the atria, a ﬁnding that may coexist with effective
hypovolaemia [67,68].
The ventricular myocardial mass is increased in some patients
in particular with septal hypertrophy [69]. Troponin I is a thin ﬁl-
ament-associated protein of the myocyte, which reﬂects cardiac
injury. This marker is elevated in patients with myocardial
ischaemia and in some patients with cirrhosis who show
increased serum concentrations [70]. These patients have a sig-
niﬁcantly lower ventricular stroke volume and left ventricular
mass index, indicating subclinical myocardial injury [70].
ANP and B-type natriuretic peptide (BNP) are secreted from
the cardiac atria and ventricles, respectively. ANP signals to
decrease blood pressure and BNP to decrease hypertrophy and
locally reduce ventricular ﬁbrosis [71]. BNP and its pro-hormone,
pro-BNP, are sensitive markers of even mild myocardial injury,
and have been found elevated in both compensated and decom-
pensated cirrhosis [72]. These peptides seem to correlate with the
severity of cirrhosis, degree of cardiac dysfunction and myocardi-
ac hypertrophy, but not to the degree of hyperdynamic circula-
tion [73] (Fig. 2) [74,75]. Since BNP and pro-BNP reﬂect the
presence of myocardial hypertrophy and cardiac dysfunction
these peptides may be useful for screening patients for the pres-
ence of cirrhotic cardiomyopathy [72,76].
The exercise capacity is reduced in a considerable number of
cirrhotic patients with a particularly low peak rate of work [77]
(Table 2). Together with the impaired cardiovascular response
to exercise, this is signiﬁcantly associated with a chronotropic
incompetence and failure to enhance systolic function [78]. The
normal stepwise increase in cardiac output following graded
exercise testing by upright bicycle ergometry is signiﬁcantly sup-
pressed in patients with cirrhosis compared with controls, and
the inability to increased cardiac performance seems most pro-
nounced in decompensated patients [79].
In advanced cirrhosis with pronounced vasodilatation, effec-
tive hypovolaemia, and arterial hypotension, the RAAS is highly0 vol. 53 j 179–190
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Fig. 2. Brain natriuretic peptide (BNP) and its pro-peptide (pro-BNP) in controls and in patients with cirrhosis, according to the Child–Turcotte classiﬁcation. BNP
and pro-BNP are signiﬁcantly increased in cirrhosis and correlate with the prolonged QT interval, indicating that the cardiac generation of BNPs reﬂects cardiac dysfunction
in cirrhosis. Data from Henriksen et al. [73].
JOURNAL OF HEPATOLOGYactivated and such patients often develop a hepatorenal syn-
drome (HRS) [15]. Patients with HRS have a low renal blood
ﬂow, glomerular ﬁltration rate, and sodium excretion that
appear to be related to a reduced systolic function. Thus, Ruiz-
Del-Arbol et al. recently reported lower cardiac output and arte-
rial blood pressure in patients with HRS, and a higher risk of
developing HRS in patients with a cardiac output lower than
6 L/min [80]. Maintenance of cardiac contractility thus seems
to be an important factor in the prevention of renal dysfunction
and HRS. Krag et al. recently demonstrated a signiﬁcant relation
between the degree of systolic and renal dysfunction and
survival in patients with decompensated cirrhosis [81]. These
studies indicate that systolic dysfunction contributes to
sodium and water-retention but on the other hand sodium
retention may also be involved in the pathophysiology of
systolic as well as diastolic dysfunction [82]. However, these
relations need to be more carefully studied in the future. Release
of inﬂammatory mediators such as tumour necrosis factor-a
(TNF-a) and interleukins may also play a role in the systolic
dysfunction. In patients with spontaneous bacterial peritonitis
(SBP), cardiac output seems lower in patients who develop
renal failure both before and after resolution of the infection
[83].
In conclusion, systolic dysfunction is often latent in cirrhotic
patients, but is unmasked by physical or pharmacological strain.
The reduced systolic function may have an impact on the devel-
opment of complications, such as sodium and water-retention as
well as ascites formation, the development of renal dysfunction
and prognosis (see Box) [9,69].Journal of Hepatology 201Diastolic dysfunction
Abnormal left ventricular diastolic function, caused by decreased
left ventricular compliance and relaxation, implies an abnormal
ﬁlling pattern of the ventricles. The transmitral blood ﬂow is
changed, with an increased atrial contribution to the late ventric-
ular ﬁlling [55] (Fig. 3). The pathophysiological background of the
diastolic dysfunction in cirrhosis is an increased stiffness of the
myocardial wall, most likely because of a combination of mild
myocardial hypertrophy, ﬁbrosis, and subendothelial oedema
[84]. There is experimental as well as clinical evidence that
increased sodium intake may lead to the development of myocar-
dial hypertrophy [82,85]. Therefore sodium retention per se may
contribute to diastolic dysfunction in cirrhosis. The increase in
myocardial stiffness is also reﬂected by other parameters of dia-
stolic dysfunction, such as a prolonged time for the ventricles to
relax after diastolic ﬁlling at a speciﬁc end-diastolic volume,
which reﬂects an increased resistance to the ventricular inﬂow,
Fig. 3 [55,65,69]. With Doppler echocardiography, Finucci et al.
found impaired left ventricular relaxation, decreased E/A ratio,
and delayed early diastolic transmittal ﬁlling in patients with cir-
rhosis compared with controls [65]. This was later conﬁrmed by
Pozzi et al. and Torregrosa et al., who revealed a complex pattern
of diastolic dysfunction in cirrhosis which was most pronounced
in patients with ascites [12,86].
ANP is regarded as a marker of volume overload and is found
increased in decompensated cirrhosis [87]. ANP is released by
stretch of the atrial ﬁbers such as in patients with ascites where
the right atrium has been reported increased partly because of0 vol. 53 j 179–190 183
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Fig. 3. Schematic illustration of the transmitral Doppler ﬂow proﬁle. Peak E
denotes the early ﬁlling of the ventricle and peak A the late atrial contribution.
Diastolic dysfunction induces characteristic changes in the ﬂow pattern, including
increased E/A ratio and prolonged deceleration time (DT). The lower diagrams
show a normal ﬁlling pattern (left) and a ﬁlling pattern indicating diastolic
dysfunction (right).
Reviewvolume overload with expanded blood volume [71,87]. However,
the interpretation of the increased ANP in patients who from a
functional point of view suffer from effective hypovolaemia is
complex. Nazar et al. recently reported a prevalence of 57%
among 102 patients with cirrhosis, with a higher degree of liver
failure and circulatory dysfunction and higher concentrations of
ANP [88]. The RAAS and ANP both contribute to volume regula-
tion and compliance, and seem to be associated with the degree
of diastolic dysfunction in cirrhotic, as well as in non-cirrhotic,
portal ﬁbrosis [89]. On the other hand, volume and pressure over-
load stretches myocardial ﬁbres and activates the intracardiac
renin-angiotensin-system [90]. Therefore, the RAAS may be
directly as well as indirectly involved in diastolic dysfunction in
cirrhosis. Patients with diastolic dysfunction are particularly sen-
sitive to volume changes that occur, for example, in relation to
insertion of a TIPS. Portal decompression with a TIPS may lead
to a further increase in the left atrial diameter and pulmonary
capillary wedged pressure, which indicates that the cirrhotic
heart is unable to receive an adequate increased preload [91–
93]. Thus, Cazzaniga et al. investigated the diastolic function in
32 cirrhotic patients after TIPS insertion and found that it pre-
dicted death after TIPS [94]. Changes in diastolic function appear
most prominent in patients with severe decompensation, and in
these patients the combination of myocardial hypertrophy, con-
tractile dysfunction, changes in heart volumes, and diastolic dys-
function may add to a cirrhotic cardiomyopathy [66,69,79,95].
The increase in diastolic volumes after TIPS seems, however, to
normalise after months but with persistence of a mild left ven-
tricular hypertrophy [93]. Moreover, reduced diastolic function
seems to be associated with slower mobilisation of ascites [11].
After liver transplantation, diastolic function seems to improve
in some patients, but the results are sparse [12,96]. Pozzi et al.
recently demonstrated that anti-aldosterone treatment with K-
canrenoate in cirrhosis ameliorated cardiac structure by reducing
left ventricular wall thickness and volume, but this treatment had
almost no effects on systolic and diastolic function [97].
In conclusion, there is evidence that the diastolic function is
impaired particularly in patients with advanced cirrhosis and184 Journal of Hepatology 201large ascites, and that indicators of diastolic dysfunction may
contain prognostic information on the course of procedures that
may affect ﬁlling of the ventricles such as TIPS insertion.
Prolongation of the QT interval
The main electrocardiographic change in cirrhosis is a prolonga-
tion of the QT interval adjusted for heart rate. It has been
known for a long time that it is prolonged in up to 50% of
patients with cirrhosis [1]. In alcoholic patients, prolonged QT
interval is associated with an increased risk of sudden cardiac
death [98]. In patients with cirrhosis, the prolonged QT interval
is unrelated to the aetiology of the liver disease, and it is seen in
both alcoholic and non-alcoholic liver diseases [98–100]. How-
ever, in cirrhosis, the duration of the QT interval is associated
with indicators of autonomic dysfunction and is partly revers-
ible after liver transplantation [101–103]. In a minority of the
patients, the QT interval may worsen after liver transplantation
[104,105]. In their study of 107 cirrhotic patients, Bernardi et al.
showed that the prolonged QT interval was correlated with the
degree of liver dysfunction and circulating plasma noradrenaline
[10]. In that study, the QT interval was also related to survival,
but others have been unable to conﬁrm an effect on mortality
[106]. The QT interval is prolonged in both non-cirrhotic and
cirrhotic portal hypertension, and the observation of a further
increase after TIPS insertion suggests that portosystemic shunt-
ing may be responsible for the altered ventricular repolarisation
[107,108]. The ﬁnding that the QT interval is also prolonged in
patients with only mild portal hypertension adds to the
assumption that the portosystemic shunting per se is of impor-
tance [109]. Acute non-selective b-blockade has been shown to
reduce the prolonged QT interval towards normal values in
patients with cirrhosis [110]; it could therefore constitute a
future indication for b-blocker treatment. Recently, Zambruni
et al. showed that chronic b-blockade shortened the QT interval
but only in patients with a prolonged interval before treatment
[111]. Life-threatening arrythmias are, however, uncommon in
cirrhosis and until now there is little evidence that treatment
with b-blockers prevent their occurrence. At present, QT interval
prolongation per se in patients with cirrhosis is therefore not an
indication for treatment with b-blockers. Studies on the disper-
sion of the QT interval (i.e. difference between the longest and
shortest interval) have shown a normal diurnal variation, and
the combination of a prolonged interval and a normal dispersion
suggests a delayed myocyte repolarisation in cirrhosis [112].
Electromechanical uncoupling is a functional disturbance
between the electrical and mechanical coupling, and has been
found in experimental cirrhosis [31,50]. Bernardi et al. mea-
sured systolic time intervals and reported a reduced cardiovas-
cular responsiveness to exercise, despite enhanced sympathetic
nervous activity [57]. These ﬁndings indicate that the impair-
ment of cardiac contractility is partly based on an abnormal
electromechanical coupling. Among 48 cirrhotic patients and
17 controls, we found a signiﬁcant difference between the elec-
trical and mechanical systole, the latter being signiﬁcantly
longer in patients with cirrhosis, whereas, as expected, there
was a direct relation between the QT interval and the duration
of the mechanical systole in the controls [113] (Fig. 4). This sug-
gests an altered cardiac excitation–contraction coupling with a
compromised association between the electrical and mechanical
function of the cirrhotic heart [8].0 vol. 53 j 179–190
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Fig. 4. Mechanical and electrical time intervals from the aortic pressure curve and electrocardiogram. (A) Pa, arterial pressure as a function of time; tP, time to peak
pressure; tS, systolic time; tD, diastolic time; tRR, time of one heart cycle; QT interval, the time from the start of the Q wave to the end of the T wave. (B) Difference between
electrical and mechanical systole time (Dt = QT  tS) in controls and patients with cirrhosis. Data from Henriksen et al. [113].
JOURNAL OF HEPATOLOGYIn conclusion, there is a large body of evidence of cardiac con-
ductance abnormalities in cirrhosis, which may increase the risk
of cardiac events. The electromechanical changes may be aggra-
vated after TIPS insertion and may be partly reversible after liver
transplantation.
Cardiac autonomic dysfunction
Reduced baroreﬂex-sensitivity has been shown to occur in cir-
rhosis as part of a general cardiovascular autonomic dysfunction
[3,24,25,100,112,114]. In a study of 105 patients with cirrhosis,
we found a reduced baroreﬂex-sensitivity, which was signiﬁ-
cantly related to central haemodynamics and biochemical
characteristics [5]. These results suggest that a reduced barore-
ceptor-sensitivity owing to the severity of the liver disease, is
associated with the cardiac dysfunction in cirrhosis [5]. Since reg-
ulation of the arterial blood pressure plays an important role in
the development of ﬂuid retention and renal function, a reduced
baroreﬂex-sensitivity will further impair renal sodium and water
excretion in these patients. The baroreﬂex-sensitivity is reduced
after exposure to hypoxia such as, for example, a sojourn at high
altitude, but supply of oxygen to cirrhotic patients does not seem
to ameliorate the low baroreﬂex-sensitivity [115]. A considerableJournal of Hepatology 201number of cirrhotic patients show a reduced heart rate variabil-
ity, which correlates with the severity of the disease, central hyp-
ovolaemia, and the degree of portal hypertension [26,108,112].
In conclusion, there are several indications that the reduced
baroreﬂex-sensitivity and heart rate variability contribute to
the cardiac dysfunction in cirrhosis.
Cardiac performance after TIPS
TIPS insertion leads to an acute increase in the right cardiac pre-
load, because of acute translocation of portal venous blood into
the systemic circulation. This results in a worsening of the hyper-
dynamic state with a further increase in cardiac output, stroke
volume and left and right end-diastolic volumes and a decrease
in the systemic vascular resistance [93,116–118]. It has been
debated whether the effects of TIPS are transient or more sus-
tained. Studies that describes short-term effects on the hyperdy-
namic circulation [91,119,120] as well as long-term effects
(>6 months) have been published [92,121]. A sustained rise in
cardiac output and a reduction in the systemic vascular resis-
tance may persist for at least 1 year post-TIPS. Furthermore, TIPS
insertion can lead to high-output congestive heart failure with
rises in pulmonary arterial and capillary pulmonary wedge0 vol. 53 j 179–190 185
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pressures [122–124], although clinically signiﬁcant heart failure
occurs in relatively few patients [125]. The acute increase in car-
diac output seems to attenuate, despite the persistence of
increased pulmonary vascular resistances [119,126]. After 6–
12 months, cardiac output and the systemic vascular resistance
tend to normalise, despite an unchanged degree of portosystemic
shunting [92,93,120]. The combined increase in left atrial diame-
ter, the pulmonary capillary wedge pressure and total pulmonary
resistance most likely reﬂect a diastolic dysfunction of the left
ventricle, as mentioned earlier, and therefore TIPS may unmask
a cirrhotic cardiomyopathy [91,92]. Prolongation of the QT inter-
val as seen in patients with cirrhosis and portal hypertension,
may also worsen after TIPS insertion in cirrhotic, as well as
non-cirrhotic, portal hypertensive patients [107].
In conclusion, TIPS insertion may acutely worsen the hyperdy-
namic circulation, but it seems to attenuate over time. TIPS inser-
tion is associated with an increased risk of heart failure and both
haemodynamic and electrophysiological changes seem to be
affected.% 
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Fig. 5. Illustration of reversibility of systolic dysfunction in patients with
cirrhosis and controls. The change in heart rate (dHR), cardiac index (dCI), and
left-ventricular ejection fraction (dEF) after stress ventriculography signiﬁcantly
improved following liver transplantation (Ltx). *p <0.05. **p <0.01. Figure based
on data from Torregrosa et al. [12].Cardiac function and liver transplantation
With implantation of a new liver, the circulating concentrations
of cardiotoxic and vasoactive substances should be reduced and
liver transplantation should therefore improve the circulatory
changes, including the hyperdynamic circulation. However, some
authors have seen persistence of the increased cardiac output for
up to two years after liver transplantation, whereas others have
reported an immediate attenuation of the hyperdynamic circula-
tion [127–129]. Hence, the time course of the haemodynamic
adaptation after liver transplantation is not yet completely
understood. The events occurring during the intraoperative per-
iod should be separated from the immediate postoperative and
more sustained events. The surgical procedure signiﬁcantly stres-
ses the heart by a sudden reduction in the cardiac preload, result-
ing in a decrease in cardiac output [130]. Bleeding and ﬂuid losses
during the operation can further reduce the cardiac output. Pul-
monary oedema has been observed in a considerable number of
patients partly because of excessive ﬂuid administration
[60,130]. Another critical period during the operation is that of
reperfusion of the graft, which can result in the occurrence of a
post-reperfusion syndrome with cardiac instability, reduced arte-
rial blood pressure and heart rate [130]. However, at present
there is no reliable method of identifying patients who are sus-
ceptible to developing these cardiac complications. Recently,
Therapondos et al. reported serum BNP as a predictor of cardiac
failure in the early post transplantation period [96]. However,
Donovan et al. identiﬁed only a few patients with left ventricular
dysfunction postoperatively, and all these patients had a normal
preoperative cardiac function, and hence it was not possible to
predict perioperative cardiac failure in this study [60]. Abnormal
cardiac responses during transplantation have been related to a
longer postoperative intubation time [131]. Interestingly, in that
study, hyponatraemia and indicators of effective hypovolaemia
predicted an abnormal cardiac response.
Postoperatively, there is a decrease in cardiac output, heart
rate, pulmonary artery pressure, and an increase in arterial blood
pressure and systemic vascular resistance [128,129,132].
Recently, Torregrosa et al. noted a signiﬁcant improvement in
cardiac performance and a reduction in myocardial mass
between six and 12 months after liver transplantation [12]. Fur-186 Journal of Hepatology 201thermore, diastolic and systolic function improved signiﬁcantly
during this period (Fig. 5).
More than 80% of patients with end-stage liver disease may
have an autonomic dysfunction before liver transplantation
[101]. About two-thirds of the patients with cirrhosis have an
autonomic dysfunction and show improvement after liver trans-
plantation [101,131,133]. The prolonged QT interval reverses in
at about half of the patients after liver transplantation, probably
as a result of diminished portosystemic shunting [101,102,105].
But in a minority of the patients, the QT interval may worsen
after liver transplantation [104].
In conclusion, liver transplantation is the ultimate treatment
for patients with end-stage liver disease, but perioperatively it
exerts a considerable stress on the cirrhotic heart. Identiﬁcation
of patients at risk of developing cardiac failure is difﬁcult. Dobu-
tamine stress test has been applied to identify patients at risk of
development cardiac complications but at present we need a
more sensitive and speciﬁc test to identify those patients that
develop cardiac failure after liver transplantation. Postopera-
tively, cardiac function seems to normalise with improvements
in cardiac hypertrophy, diastolic and systolic function, and QT
interval, but more studies on the cardiac effects are needed.Summary and conclusion
There is considerable experimental evidence of a cirrhotic cardio-
myopathy from in vitro and animal studies in cirrhotic models of
cardiac dysfunction (see Box). Patients with advanced cirrhosis
present with a circulatory hyperdynamic dysfunction as part of
a multi-organ failure with impaired function and perfusion of
kidneys, lungs, brain, skin, muscles, and the heart. While normal
at rest, during stress the cardiac performance and systolic func-
tion are clearly impaired relative to the liver dysfunction. The
impaired cardiac contractility in cirrhotic cardiomyopathy is dif-
ferent from that seen in alcoholic heart muscle disease. Among
signiﬁcant pathophysiological mechanisms are reduced b-adren-
ergic receptor signal transduction and a defective cardiac electro-0 vol. 53 j 179–190
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mechanical coupling. The cirrhotic heart may be overloaded with
a high-output failure and at the same time be hyperdynamic with
a diastolic dysfunction; strain may unmask a latent congestive
heart failure. No speciﬁc therapy can be recommended for this
condition, and management of patients with cirrhotic cardiomy-
opathy should be directed against the congested heart failure and
include conventional treatment for pulmonary stasis with diuret-
ics. Vasodilators, like ACE-inhibitors, should not be used due to
the risk of further aggravation of the systemic vasodilatory state.
Aldosterone antagonists may have beneﬁcial effects in terms of a
reduction in left ventricular dilatation and wall thickness and
improvement of diastolic function. Cardiac glycosides do not
seem to improve cardiac contractility in cirrhotic cardiomyopa-
thy. In addition to their lowering effect on portal pressure, b-
blockers may reduce the hyperdynamic load and improve the
prolonged QT interval, but future research should elucidate
whether they also improve the contractile dysfunction, electro-
mechanical abnormalities, and mortality. In addition, cirrhotic
cardiomyopathy seems to play a role in the development of
HRS. Lastly, liver transplantation improves most of the cardiac
dysfunction.
Box: Key messages of cirrhotic cardiomyopathiesConﬂicts of interest
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